Bio-Techne

-4.09%

More reviews (1)

Live  

Bio-Techne is a global life sciences company that provides innovative research tools and solutions to scientists and clinicians. The company was established in 1976 and is headquartered in Minneapolis, Minnesota. It operates through four key divisions: Bio-Techne, R&D Systems, Novus Biologicals, and ProteinSimple.
Bio-Techne's products include proteins, antibodies, assays, and reagents for a wide range of research areas such as cell biology, immunology, neuroscience, and drug discovery. The company also offers services such as protein analysis, contract manufacturing, and custom antibody development.
Bio-Techne has a strong global presence, with offices and distribution centers in North America, Europe, and Asia-Pacific. It serves customers in over 160 countries and has collaborations with leading pharmaceutical and biotech companies.
The company is committed to advancing science and improving human health through its products and services. It invests heavily in research and development to continuously innovate and expand its product portfolio. Bio-Techne also supports the scientific community through educational initiatives and partnerships with academic institutions.
In addition to its research tools and solutions, Bio-Techne has a strong focus on corporate social responsibility and sustainability. It has implemented various initiatives to reduce its environmental impact and support the communities where it operates.
Overall, Bio-Techne is a leading company in the life sciences industry, known for its high-quality products, scientific expertise, and commitment to improving human health.

Bio-Techne is a company that makes special tools and products for scientists and researchers who study living things, like cells and proteins. Think of them like a big toolbox full of gadgets that help scientists learn more about diseases, how our bodies work, and even how to create new medicines.
The way Bio-Techne makes money is by selling these products to universities, hospitals, and companies that do research. They have things like proteins, antibodies (which help scientists find and study other proteins), and machines that help measure and analyze different biological samples. Whenever researchers need these tools, they buy them from Bio-Techne.
Bio-Techne is successful because they make high-quality products that scientists trust. If scientists can rely on their tools, they’ll keep coming back to buy more, and that helps the company earn money. They are also always looking for new and better ways to help researchers, which keeps them ahead of the competition.
In the future, Bio-Techne is likely to stay successful because science and research are always advancing. There will always be new discoveries to make and diseases to study, which means a continued need for their products. Plus, as technology gets better, they can create even more innovative tools that will help scientists work more efficiently, leading to more sales and growth. So, as long as there is curiosity about life and how it works, Bio-Techne will be there, helping scientists along the way!

MS4gUmVub3 duZWQgQmlv dGVjaCBDb2 1wYW55OiBC aW8tVGVjaG 5lIGlzIGEg Z2xvYmFsbH kgcmVjb2du aXplZCBiaW 90ZWNoIGNv bXBhbnkgdG hhdCBzcGVj aWFsaXplcy BpbiBwcm92 aWRpbmcgaW 5ub3ZhdGl2 ZSBzb2x1dG lvbnMgZm9y IGxpZmUgc2 NpZW5jZSBy ZXNlYXJjaC wgZGlhZ25v c3RpY3MsIG FuZCBjbGlu aWNhbCBsYW JvcmF0b3Jp ZXMuPGJyPj IuIERpdmVy c2UgUHJvZH VjdCBQb3J0 Zm9saW86IF RoZSBjb21w YW55IG9mZm VycyBhIGRp dmVyc2Ugcm FuZ2Ugb2Yg aGlnaC1xdW FsaXR5IHBy b2R1Y3RzIG luY2x1ZGlu ZyBhbnRpYm 9kaWVzLCBw cm90ZWlucy wgYXNzYXlz LCBmbG93IG N5dG9tZXRy eSwgaW1hZ2 luZywgYW5k IG1vbGVjdW xhciBiaW9s b2d5IHJlYW dlbnRzLiBU aGlzIGV4dG Vuc2l2ZSBw cm9kdWN0IH BvcnRmb2xp byBhbGxvd3 MgcmVzZWFy Y2hlcnMgYW 5kIGNsaW5p Y2lhbnMgdG 8gYWNjZXNz IGFsbCB0aG UgbmVjZXNz YXJ5IHRvb2 xzIGZvciB0 aGVpciB3b3 JrLjxicj4z LiBDdXR0aW 5nLWVkZ2Ug VGVjaG5vbG 9neTogQmlv LVRlY2huZS B1dGlsaXpl cyBjdXR0aW 5nLWVkZ2Ug dGVjaG5vbG 9neSB0byBk ZXZlbG9wIG FuZCBtYW51 ZmFjdHVyZS BpdHMgcHJv ZHVjdHMuIF RoaXMgaW5j bHVkZXMgYW R2YW5jZWQg cHJvdGVpbi BhbmQgYW50 aWJvZHkgZW 5naW5lZXJp bmcgcGxhdG Zvcm1zLCBm bG93IGN5dG 9tZXRyeSBh bmQgaW1hZ2 luZyBzeXN0 ZW1zLCBhbm QgbW9sZWN1 bGFyIGFuZC BjZWxsIGJp b2xvZ3kgdG VjaG5pcXVl cy48YnI+NC 4gRXhwZXJ0 aXNlIGluIE 11bHRpcGxl IERpc2NpcG xpbmVzOiBC aW8tVGVjaG 5lIGhhcyBl eHBlcnRpc2 UgaW4gbXVs dGlwbGUgZG lzY2lwbGlu ZXMgc3VjaC BhcyBpbW11 bm9sb2d5LC BjZWxsIGJp b2xvZ3ksIG 5ldXJvc2Np ZW5jZSwgYW 5kIG1vbGVj dWxhciBkaW Fnbm9zdGlj cy4gVGhpcy BhbGxvd3Mg dGhlIGNvbX BhbnkgdG8g cHJvdmlkZS Bjb21wcmVo ZW5zaXZlIH NvbHV0aW9u cyBmb3IgYS B3aWRlIHJh bmdlIG9mIH Jlc2VhcmNo IGFyZWFzLj xicj41LiBH bG9iYWwgUm VhY2g6IFdp dGggaGVhZH F1YXJ0ZXJz IGluIHRoZS BVbml0ZWQg U3RhdGVzLC BCaW8tVGVj aG5lIGhhcy BhIGdsb2Jh bCBwcmVzZW 5jZSB3aXRo IG1hbnVmYW N0dXJpbmcg ZmFjaWxpdG llcywgZGlz dHJpYnV0aW 9uIGNlbnRl cnMsIGFuZC BzYWxlcyBv ZmZpY2VzIG luIG11bHRp cGxlIGNvdW 50cmllcy4g VGhpcyBlbm FibGVzIHRo ZSBjb21wYW 55IHRvIHNl cnZlIGN1c3 RvbWVycyBh bGwgb3Zlci B0aGUgd29y bGQuPGJyPj YuIFN0cm9u ZyBTY2llbn RpZmljIENv bGxhYm9yYX Rpb25zOiBU aGUgY29tcG FueSBoYXMg c3Ryb25nIG NvbGxhYm9y YXRpb25zIH dpdGggbGVh ZGluZyBhY2 FkZW1pYyBh bmQgcmVzZW FyY2ggaW5z dGl0dXRpb2 5zLCB3aGlj aCBhbGxvd3 MgdGhlbSB0 byBzdGF5IG F0IHRoZSBm b3JlZnJvbn Qgb2Ygc2Np ZW50aWZpYy BhZHZhbmNl bWVudHMgYW 5kIGRldmVs b3AgbmV3IH Byb2R1Y3Rz Ljxicj43Li BDb21taXRt ZW50IHRvIF F1YWxpdHkg YW5kIFNhZm V0eTogQmlv LVRlY2huZS BoYXMgYSBz dHJpY3QgcX VhbGl0eSBj b250cm9sIH N5c3RlbSBp biBwbGFjZS B0byBlbnN1 cmUgdGhlIH NhZmV0eSBh bmQgZWZmZW N0aXZlbmVz cyBvZiBpdH MgcHJvZHVj dHMuIFRoZX kgaGF2ZSBv YnRhaW5lZC BJU08gMTM0 ODUgY2VydG lmaWNhdGlv biBhbmQgYX JlIGNvbXBs aWFudCB3aX RoIEZEQSBy ZWd1bGF0aW 9ucy48YnI+ OC4gRm9jdX Mgb24gQ3Vz dG9tZXIgU2 VydmljZTog VGhlIGNvbX BhbnkgaGFz IGEgY3VzdG 9tZXItY2Vu dHJpYyBhcH Byb2FjaCBh bmQgaXMgY2 9tbWl0dGVk IHRvIHByb3 ZpZGluZyBl eGNlcHRpb2 5hbCBjdXN0 b21lciBzZX J2aWNlLiBU aGV5IG9mZm VyIHRlY2hu aWNhbCBzdX Bwb3J0LCB0 cmFpbmluZy wgYW5kIGN1 c3RvbWl6ZW Qgc29sdXRp b25zIHRvIG 1lZXQgdGhl IHVuaXF1ZS BuZWVkcyBv ZiB0aGVpci BjdXN0b21l cnMu

VGhlIEJpby 1UZWNobmUg Y29tcGFueS dzIGJ1c2lu ZXNzIG1vZG VsIGlzIGZv Y3VzZWQgb2 4gZGV2ZWxv cGluZywgbW FudWZhY3R1 cmluZywgYW 5kIGRpc3Ry aWJ1dGluZy BoaWdoLXF1 YWxpdHkgbG lmZSBzY2ll bmNlIHJlYW dlbnRzIGFu ZCBpbnN0cn VtZW50cyB1 c2VkIGluIG Jpb21lZGlj YWwgcmVzZW FyY2ggYW5k IGNsaW5pY2 FsIGRpYWdu b3N0aWNzLi BUaGlzIGlu Y2x1ZGVzIH Byb2R1Y3Rz IHN1Y2ggYX MgYW50aWJv ZGllcywgcH JvdGVpbnMs IGFzc2F5IG tpdHMsIGFu ZCBpbnN0cn VtZW50cyBm b3IgY2VsbC BhbmQgZ2Vu ZSB0aGVyYX B5LCBpbW11 bm90aGVyYX B5LCBhbmQg bW9sZWN1bG FyIGRpYWdu b3N0aWNzLi BCaW8tVGVj aG5lIHNlbG xzIGl0cyBw cm9kdWN0cy BkaXJlY3Rs eSB0byBjdX N0b21lcnMs IGFzIHdlbG wgYXMgdGhy b3VnaCBkaX N0cmlidXRv cnMgYW5kIE 9FTSAob3Jp Z2luYWwgZX F1aXBtZW50 IG1hbnVmYW N0dXJlcikg cGFydG5lcn NoaXBzLiBU aGUgY29tcG FueSBhbHNv IHByb3ZpZG VzIGNvbnRy YWN0IHJlc2 VhcmNoIGFu ZCBtYW51Zm FjdHVyaW5n IHNlcnZpY2 VzIGZvciB0 aGUgZGV2ZW xvcG1lbnQg YW5kIHByb2 R1Y3Rpb24g b2YgY3VzdG 9tIHJlYWdl bnRzIGFuZC Bhc3NheXMu IEFkZGl0aW 9uYWxseSwg QmlvLVRlY2 huZSBoYXMg c3RyYXRlZ2 ljIGFsbGlh bmNlcyBhbm QgY29sbGFi b3JhdGlvbn Mgd2l0aCBv dGhlciBjb2 1wYW5pZXMg YW5kIG9yZ2 FuaXphdGlv bnMgdG8gYW R2YW5jZSBy ZXNlYXJjaC BhbmQgaW5u b3ZhdGlvbi BpbiB0aGUg bGlmZSBzY2 llbmNlcyBm aWVsZC4=

AI can pose several potential threats to a biotech company like Bio-Techne, particularly in the areas of substitution, disintermediation, and margin pressure.
1. Substitution: AI and advanced computational techniques can lead to the development of new methods for data analysis and interpretation in life sciences, which may substitute some of the traditional products and services that Bio-Techne offers. For instance, AI-driven platforms for drug discovery and personalized medicine can reduce the reliance on existing tools and reagents produced by Bio-Techne, affecting demand.
2. Disintermediation: AI can enable researchers and clinicians to access information and perform analyses directly without the need for intermediaries. With AI tools that allow for idepth genomic analysis or protein characterization, customers may opt to conduct their experiments ihouse, reducing their dependency on Bio-Techne’s products or services.
3. Margin Pressure: The integration of AI into biotech can lead to increased competition and a drive for cost efficiency. Companies utilizing AI technologies may be able to offer similar products at lower prices, pressuring traditional firms like Bio-Techne to lower their margins. As AI tools become more widespread and accessible, Bio-Techne may need to innovate or invest heavily in AI capabilities to remain competitive, which can impact profit margins.
In conclusion, while AI does pose potential threats in these areas, it also offers opportunities for innovation and enhancement of existing products and services. How Bio-Techne navigates these challenges will play a critical role in its ongoing competitive positioning.

The sensitivity of Bio-Techne’s earnings, cash flow, and valuation to changes in interest rates can be understood through several key factors:
1. Cost of Capital: As interest rates increase, the cost of borrowing also rises. This can impact Bio-Techne’s ability to finance new projects, acquisitions, or research and development through debt, potentially leading to higher costs and reduced profitability.
2. Discount Rate: Higher interest rates often lead to a higher discount rate applied to future cash flows in valuation models. For a company like Bio-Techne, which may expect growth in earnings and cash flows over time, a higher discount rate can significantly reduce the present value of these cash flows, leading to lower valuations.
3. Market Sentiment: Rising interest rates can affect investor sentiment and risk appetite. As rates go up, equities may be seen as less attractive compared to fixed-income investments, which could result in selling pressure on Bio-Techne’s stock, thus impacting its market valuation.
4. Impact on Revenue Growth: If interest rates lead to broader economic slowdowns, spending on biotechnology and life sciences products and services may tighten for customers, impacting Bio-Techne’s revenue growth.
5. Operational Costs: Higher interest rates can also lead to increased operational costs if the company has existing variable-rate debt. This could further squeeze margins and cash flow.
In summary, while Bio-Techne’s specific sensitivity to interest rate changes would depend on its financial structure, current debt levels, and operational strategy, the general implications of rising rates could lead to diminished earnings, strained cash flows, and a lower overall valuation.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvUn BJYjlQcHBR b2wzQ1VVN3 FMMkIud2Vi cCIgYWx0PS JCaW8tVGVj aG5lIiB0aX RsZT0iQmlv LVRlY2huZS IgIGNsYXNz PSJpbWctZm x1aWQiIGhl aWdodD05MC B3aWR0aD05 MCBsb2FkaW 5nPSdsYXp5 JyBzdHlsZT 0nYm9yZGVy LXJhZGl1cz ogNnB4Oyc+ CgogICAgIC AgICAgICAg ICAgICAgID xkaXYgc3R5 bGU9J2ZsZX g6IDE7IHRl eHQtYWxpZ2 46IGNlbnRl cjsgbWFyZ2 luLWxlZnQ6 IDVweDsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8cCBzdH lsZT0nZm9u dC1zaXplOi AyNnB4OyBj b2xvcjogIz MzMzsgbWFy Z2luLWJvdH RvbTogMTVw eDsnPgogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAg8J+TiC BXYW50IHRv IHJlYWQgbW 9yZSBhYm91 dCBCaW8tVG VjaG5lPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +SoSBMZWFy biBzbWFydG VyIHN0b2Nr IHBpY2tzIH dpdGggPGk+ IlRoZSBDaG Vja2xpc3Qg VmFsdWUgSW 52ZXN0b3Ig 4oCUIEEgU2 1hcnRlciBX YXkgdG8gUG ljayBTdG9j a3MiPC9pPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8L3A+Cg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8IS0tCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxkaXYgc3 R5bGU9J21h cmdpbi10b3 A6IDEycHg7 IGZvbnQtc2 l6ZTogMTNw eDsgY29sb3 I6ICM0NDQ7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IFNpZ24gdX Agbm93IGFu ZCBnZXQgb3 VyIGZyZWUg ZUJvb2sgCi AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICA8Yj 5UaGUgQ2hl Y2tsaXN0IF ZhbHVlIElu dmVzdG9yIO KAlCBBIFNt YXJ0ZXIgV2 F5IHRvIFBp Y2sgU3RvY2 tzPC9iPgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L2Rpdj4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgLS0+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID whLS0KICAg ICAgICAgIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nbWFyZ2 luLXRvcDog MTZweDsgZm 9udC1zaXpl OiAxNHB4Oy Bjb2xvcjog IzQ0NDsgZm 9udC1mYW1p bHk6IC1hcH BsZS1zeXN0 ZW0sIEJsaW 5rTWFjU3lz dGVtRm9udC wgU2Vnb2Ug VUksIFJvYm 90bywgSGVs dmV0aWNhIE 5ldWUsIHNh bnMtc2VyaW Y7IGxpbmUt aGVpZ2h0Oi AxLjY7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIEhh dmUgeW91IG hlYXJkIGFi b3V0IG91ci BzaG9ydCA8 c3Ryb25nIH N0eWxlPSdm b250LXdlaW dodDogNjAw Oyc+RGFpbH kgVmlkZW8g TmV3c2xldH Rlcjwvc3Ry b25nPj8KIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIDxhIG hyZWY9J2h0 dHBzOi8vd3 d3Lmluc2ln aHRmdWx2YW x1ZS5jb20v bmV3c2xldH Rlci5waHAn IHRhcmdldD 0nX2JsYW5r JyBzdHlsZT 0nY29sb3I6 ICMwMDdCRk Y7IHRleHQt ZGVjb3JhdG lvbjogbm9u ZTsgZm9udC 13ZWlnaHQ6 IDUwMDsgbW FyZ2luLWxl ZnQ6IDZweD snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIEZp bmQgb3V0IG 1vcmUKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9kaXY+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIC0tPgog ICAgICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC AgICAgPC9k aXY+CiAgIC AgICAgICAg IDwvZGl2Pg ogICAgICAg ICAgICAKIC AgICAgICAK ICAgICAgIC A8c3BhbiBj bGFzcz0nYm x1cnJlZC10 ZXh0Jz4KIC AgICAgICAg ICAgTVM0Z1 FtbHZMViBS bFkyaHVaU0 JEIGIzSndi M0poZEcgbH ZiaUIzWVhN ZyBabTkxYm 1SbFpDIEJw YmlBeE9UYz IgSUdGdVpD QjNZWCBNZ2 IzSnBaMmx1 IFlXeHNlU0 JyYm0gOTNi aUJoY3lCVS BaV05vYm1V Z1EyIDl5Y0 c5eVlYUnAg YjI0dVBHSn lQaiBJdUlG Um9aU0JqIG IyMXdZVzU1 SUggTjBZWE owWldRZyBZ WE1nWVNCdF lXIDUxWm1G amRIVnkgWl hJZ2IyWWdh VyA1emRISj FiV1Z1IGRI TWdkWE5sWk MgQm1iM0ln YVcxdCBkVz V2WkdsaFoy IDV2YzNScF kzTXMgSUhO d1pXTnBabS BsallXeHNl U0JtIGIzSW diV1ZoYzMg VnlhVzVuSU dONSBkRzly YVc1bGN5IE JoYm1RZ2FX NTAgWlhKbV pYSnZibiBN dUlEeGljaj R6IExpQkpi aUF4T1Qgaz VMQ0IwYUdV ZyBZMjl0Y0 dGdWVTIEJo WTNGMWFYSm wgWkNCU0pr UWdVMyBsem RHVnRjeXdn IFlTQnNaV0 ZrYVcgNW5J SE4xY0hCcy BhV1Z5SUc5 bUlIIEJ5Yj NSbGFXNXog TENCaGJuUn BZbSA5a2FX VnpMQ0JoIG JtUWdhVzF0 ZFcgNXZZWE 56WVhrZyBj SEp2WkhWam RIIE11SUZS b2FYTWcgWV dOeGRXbHph WCBScGIyNG diV0Z5IGEy VmtJSFJvWl MgQmlaV2Rw Ym01cCBibW NnYjJZZ1Ft IGx2TFZSbF kyaHUgWmVL QW1YTWdaWC Bod1lXNXph Vzl1IElHbH VkRzhnZEcg aGxJR3hwWm 1VZyBjMk5w Wlc1alpYIE 1nYldGeWEy VjAgTGp4aW NqNDBMaSBC Q2FXOHRWR1 ZqIGFHNWxJ R2hoY3kgQm hJR2RzYjJK aCBiQ0J3Y2 1WelpXIDVq WlN3Z2QybD AgYUNCdmNH VnlZWCBScG IyNXpJR2x1 IElHOTJaWE lnTlQgQWdZ MjkxYm5SeS BhV1Z6SUdG dVpDIEJqZF hOMGIyMWwg Y25NZ2FXNG diMyBabGNp QXhNelVnIF kyOTFiblJ5 YVcgVnpMan hpY2o0MSBM aUJVYUdVZ1 kyIDl0Y0dG dWVlS0EgbV hNZ2NISnZa SCBWamRITW dZWEpsIElI VnpaV1FnYV cgNGdkbUZ5 YVc5MSBjeU JtYVdWc1pI IE1nYzNWam FDQmggY3lC dFpXUnBZMi BGc0lISmxj MlZoIGNtTm 9MQ0JrY24g Vm5JR1JsZG 1WcyBiM0J0 Wlc1MExDIE JoYm1RZ1pH bGggWjI1dm MzUnBZMyBN dVBHSnlQal l1IElFSnBi eTFVWlcgTm 9ibVhpZ0ps eiBJR2hsWV dSeGRXIEZ5 ZEdWeWN5Qm ggY21VZ2JH OWpZWCBSbF pDQnBiaUJO IGFXNXVaV0 Z3YjIgeHBj eXdnVFdsdS BibVZ6YjNS aExDIEJoYm 1RZ2FYUWcg YUdGeklHMW hibiBWbVlX TjBkWEpwIG JtY2dabUZq YVcgeHBkR2 xsY3lCcCBi aUIwYUdVZ1 ZXIDVwZEdW a0lGTjAgWV hSbGN5d2dR MiBGdVlXUm hMQ0JEIGFH bHVZU3dnWV cgNWtJRVYx Y205dyBaUz Q4WW5JK055 IDRnVkdobE lHTnYgYlhC aGJua2dhRy BGeklHOTJa WElnIE15dz RNREFnWlcg MXdiRzk1Wl dWeiBJSGR2 Y214a2QyIG xrWlM0OFlu SSsgT0M0Z1 NXNGdNaiBB eU1Dd2dRbW x2IExWUmxZ Mmh1WlMgQj NZWE1nYm1G dCBaV1FnYj I1bElHIDlt SUhSb1pTQl ggYjNKc1pP S0FtWCBNZ1 RXOXpkQ0JK IGJtNXZkbU YwYVggWmxJ RU52YlhCaC BibWxsY3lC aWVTIEJHYj NKaVpYTWcg YldGbllYcH BibSBVdVBH SnlQamt1IE lGUm9aU0Jq YjIgMXdZVz U1SUdseiBJ R3hwYzNSbF pDIEJ2YmlC MGFHVWcgVG tGVFJFRlJJ SCBOMGIyTn JJR1Y0IFky aGhibWRsSU ggVnVaR1Z5 SUhSbyBaU0 IwYVdOclpY IElnYzNsdF ltOXMgSUZS RlEwZ3VQRy BKeVBqRXdM aUJDIGFXOH RWR1ZqYUcg NWxJR2x6SU dOdiBiVzFw ZEhSbFpDIE IwYnlCemRY TjAgWVdsdV lXSnBiRyBs MGVTQmhibV FnIGFHRnpJ SEpsWkggVm paV1FnYVhS eiBJR05oY2 1KdmJpIEJs YldsemMybH YgYm5NZ1lu a2dOeiBBbE lITnBibU5s IElESXdNVF V1SUUgbDBJ R0ZzYzI4Zy BhR0Z6SUdF Z2NIIEp2Wj NKaGJTQnAg YmlCd2JHRm paUyBCMGJ5 QnlaV1IxIF kyVWdjMmx1 WjIgeGxMWF Z6WlNCdyBi R0Z6ZEdsak lHIGx1SUds MGN5QncgY2 05a2RXTjBj eSBCaGJtUW djR0ZqIGEy Rm5hVzVuTG ogeGljajR4 TVM0ZyBTVz RnWVdSa2FY IFJwYjI0Z2 RHOGcgYVhS eklHMWhhVy A0Z1lYSmxZ WE1nIGIyWW dabTlqZFgg TXNJRUpwYn kxVSBaV05v Ym1VZ1lXIH h6YnlCdlpt WmwgY25NZ1 kzVnpkRyA5 dElHMWhibl ZtIFlXTjBk WEpwYm0gY2 djMlZ5ZG1s aiBaWE1nWm 05eUlHIE4x YzNSdmJXVn kgY3lCcGJp QjBhRyBVZ1 ltbHZkR1Zq IGFDQnBibV IxYzMgUnll UzQ4WW5JKy BNVEl1SUZS b1pTIEJqYj Ixd1lXNTUg SUdoaGN5Qn laVyBObGFY WmxaQ0J0IG RXeDBhWEJz WlMgQmhkMk Z5WkhNZyBZ VzVrSUhKbF kyIDluYm1s MGFXOXUgSU dadmNpQnBk SCBNZ2NISn ZaSFZqIGRI TWdZVzVrSU ggTmxjblpw WTJWeiBMQ0 JwYm1Oc2RX IFJwYm1jZ2 RHaGwgSUVO cGRHVkJZaS BCaGQyRnla Q0JtIGIzSW dRbVZ6ZEMg QkJiblJwWW 05ayBlU0JU ZFhCd2JHIG xsY2lCaGJt UWcgZEdobE lGTmphVyBW dWRHbHpkSF BpIGdKa2dR Mmh2YVcgTm xJRUYzWVhK ayBJR1p2Y2 lCQ1pYIE4w SUU1bGR5Qk 0gYVdabElG TmphVyBWdV kyVnpJRkJ5 IGIyUjFZM1 F1UEcgSnlQ akV6TGlCQy BhVzh0VkdW amFHIDVsSU dseklHbHUg ZG05c2RtVm tJRyBsdUlI WmhjbWx2IG RYTWdjR2hw YkcgRnVkR2 h5YjNCcCBZ eUJsWm1adm NuIFJ6TENC cGJtTnMgZF dScGJtY2da RyA5dVlYUn BibWNnIFpu VnVaSE1nWV cgNWtJSEJ5 YjJSMSBZM1 J6SUhSdklI IE4xY0hCdm NuUWcgYldW a2FXTmhiQy BCeVpYTmxZ WEpqIGFDQm hibVFnY0gg SnZkbWxrYV c1biBJR1pw Ym1GdVkyIG xoYkNCemRY QncgYjNKME lHWnZjaSBC dmNtZGhibW w2IFlYUnBi MjV6SUggZH ZjbXRwYm1j ZyBkRzkzWV hKa2N5IEJ6 YjJOcFlXd2 cgYW5WemRH bGpaUyBCaG JtUWdaWEYx IFlXeHBkSG t1UEcgSnlQ akUwTGlCSi BiaUF5TURJ eExDIEJDYV c4dFZHVmog YUc1bElHRn VibSA5MWJt TmxaQ0JoIE lIQmhjblJ1 WlggSnphR2 x3SUhkcCBk R2dnZEdobE lFIEpwYkd3 Z1lXNWsgSU UxbGJHbHVa RyBFZ1IyRj BaWE1nIFJt OTFibVJoZE cgbHZiaUIw YnlCayBaWF psYkc5d0lH IEZ1WkNCdF lXNTEgWm1G amRIVnlaUy BCaElHNXZk bVZzIElIQn liM1JsYVcg NHRZbUZ6Wl dRZyBRMDlX U1VRdE1UIG tnZG1Galky bHUgWlM0OF luSStNVCBV dUlGUm9aU0 JqIGIyMXdZ VzU1NG8gQ1 pjeUJ0YVhO eiBhVzl1SU dseklIIFJ2 SUhCeWIzWn AgWkdVZ2FX NXViMyBaaG RHbDJaU0Iw IGIyOXNjeU JoYm0gUWdj bVZ6YjNWeS BZMlZ6SUhS dklHIEZrZG 1GdVkyVWcg ZEdobElIVn VaRyBWeWMz UmhibVJwIG JtY2diMlln WW0gbHZiRz luZVNCaCBi bVFnZEc4Z1 lXIE5qWld4 bGNtRjAgWl NCMGFHVWda RyBselkyOT JaWEo1IElH RnVaQ0JrWl ggWmxiRzl3 YldWdSBkQ0 J2WmlCdVpY IGNnZEdobG NtRncgWlhW MGFXTnpMZy A9PQogICAg ICAgIDwvc3 Bhbj4KICAg ICAgICAKIC AgICAgICA=